Lv1
78 积分 2023-02-20 加入
Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial
2天前
已完结
Efficacy and safety of darolutamide in Black/African-American patients from the phase III ARAMIS study
2天前
已关闭
Real-world analysis of androgen receptor inhibitors in US patients with nonmetastatic castration-resistant prostate cancer: DEAR-EXT study
2天前
已完结
Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
3天前
已完结
nmCRPC, a look in the continuous care of prostate cancer patients: state of art and future perspectives
3天前
已完结
MARGINAL ZONE LYMPHOMA INTERNATIONAL PROGNOSTIC INDEX (MZL‐IPI): A PROGNOSTIC SCORE FOR THE ENTIRE SPECTRUM OF MARGINAL ZONE LYMPHOMAS. A FIL AND SPORE‐MER STUDY
24天前
已完结
Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial
25天前
已完结
First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosa-associated lymphoid tissue lymphoma (MALT2008-01): a multicentre, single-arm, phase 2 trial
26天前
已完结
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
26天前
已完结
Marginal Zone Lymphoma: 2026 Update on Diagnosis and Management
26天前
已完结
皖公网安备34019202002308
